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Abstract
Background: Delirium is a neurobehavioural syndrome that frequently develops in the postoperative setting. The
incidence of elderly patients who develop delirium during hospital stay ranges from 10 to 80% (Schonauer et al., J Pept
Sci. 2017). Delirium was first described more than half a century ago in the cardiac surgery population (Blachy and Starr,
Am J Psychiatry 121:371–5, 1964), where it was already discovered as a state that might be accompanied by serious
complications such as prolonged ICU and hospital stay, reduced quality of life and increased mortality. Furthermore, the
duration of delirium is associated with worse long-term cognitive function in the general ICU population (Sessler et al.,
Am J Respir Crit Care Med 166:1338–44, 2002). This long-term experience with delirium suggests a high socioeconomic
burden and has been a focus of many studies (Nishio et al., Crit Care Med 5:953–7, 1997; Ehlenbach et al., JAMA 303:763–
70, 2010; Jahangir et al., World J Cardiol 3:383–7, 2011; Abegunde et al., Lancet 370:1929–1938, 2007; Darmon et al.,
Intensive Care Med 43:829-840, 2017; Marino et al., J Nephrol 28:717–24, 2015; Ng LL et al., J Am Coll Cardiol 69:56–69,
2017; Sezen et al., J Pharmacol Exp Ther 287:238–45, 1998; Kim et al., Ann Lab Med 37:388–97, 2017). Due to the
multifactorial origin of delirium, we have several but no incontestable options for prevention and symptomatic
treatment. Overall, delirium represents a high burden not only for patient and family members, but also for the medical
care team that aims to prevent postoperative delirium to avoid serious consequences associated with it. The purpose of
this study is to determine whether postoperative delirium can be prevented by the combination of established
preventive agents. In addition, measured levels of pre- and postoperative cortisol, neuron specific enolase (NSE) and
S-100β will be used to investigate dynamics of these parameters in delirious and non-delirious patients after surgery.
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Methods/design: The Baden PRIDe Trial is an investigator-initiated, phase IV, two-centre, randomised, placebo-controlled,
double-blind clinical trial for the prevention of delirium with haloperidol, ketamine, and the combination of both vs.
placebo in 200 patients scheduled for surgery. We would like to investigate superiority of one of the three treatment
arms (i.e., haloperidol, ketamine, combined treatment) to placebo.
Discussion: There is limited but promising evidence that haloperidol and ketamine can be used to prevent delirium.
Clinical care for patients might improve as the results of this study may lead to better algorithms for the prevention of
delirium.
Trial registration: ClinicalTrials.gov, NCT02433041. Registered on 7 April 2015.
Swiss National Clinical Trial Portal, SNCTP000001628. Registered on 9 December 2015.
Keywords: Postoperative delirium, Delirium prevention, Haloperidol, Ketamine, Randomised clinical trial, NSE, S100β,
MMSE, Nu-DESC, ICDSC, DOS
Strengths and limitations of the study
 The study’s main strength is the implementation of
a promising preventative method for a tenacious
problem: the lack of adequate and dependable
prevention of postoperative delirium, a condition
first described more than five decades ago [1, 2].
 The trial tests the preventative properties of
ketamine and haloperidol, which can be
demonstrated in a broad field of surgical procedures.
 No adverse events are to be expected from the
administration of the trial medication as a
weight-dependent single dose following careful
consideration of exclusion criteria.
 Evidence from previous studies suggests a
considerable benefit for prevention of delirium along
with increased comfort and safety for patients
involved in the study.
 The Baden PRIDe Trial will primarily recruit
patients from two Swiss anaesthesiology
departments to achieve the calculated sample size
within the foreseen time period.
 The study is limited by the heterogeneous risk
constellation of our patients considering the risk
factors for delirium that have been gathered to date.
 These variable conditions will not be addressed by the
evaluation of a score to assess patient comorbidity
(e.g., Simplified Acute Physiology Score II).
Background
First described more than half a century ago [1], numer-
ous risk factors for delirium have been detected over the
last decades [3], emphasising the importance of delirium
prevention. Despite of being focus of long lasting research,
[4–9] incidence remains high [10, 11]. While study data
offer some possibilities, there are no strictly defined rules
of action for pharmacological or neuropsychological pre-
vention for delirium in general [12]. Hospitals have
various algorithms for prevention and treatment of delir-
ium. This randomised, double-blind, placebo-controlled
study aims to compare haloperidol [13] and ketamine [13,
14], two agents that have been suggested to prevent post-
operative delirium, separately and in combination.
As with all pharmacological treatment options, drug side
effects have always to be taken into consideration and care-
ful observation of patients is mandatory. Common side ef-
fects of haloperidol include agitation, sleep disorders,
extrapyramidal symptoms, overshooting body and extrem-
ity movements and headache. Frequent side effects of keta-
mine include psychiatric disorders (wake-up reactions such
as hallucinations, vivid dreams, nightmares, confusion,
motor restlessness, conspicuous behaviour and agitation),
neurological disorders (nystagmus, tonic and clonic move-
ments, increased muscle tone and elevated intracranial
pressure except for controlled ventilation), eye disorders
(diplopia, visual disturbance), cardiac problems (tachycardia,
hypertension), respiratory problems (elevated respiratory
rate), gastrointestinal symptoms (nausea and vomiting) and
cutaneous symptoms (erythema, morbilliform exanthema).
While haloperidol seems to be the drug most often
administered for delirium prevention [15] and treatment
[12], ketamine demonstrates anti-inflammatory proper-
ties that might explain its beneficial effect on limiting
delirium emergence [16]. A recently published study
found that the administration of a sub-anaesthetic dose
of ketamine in patients aged 60 years or older undergo-
ing major surgery did not reduce the incidence of
postoperative delirium or affect postoperative pain [17].
In this study, the findings were contrary to the trial
hypothesis and conflicted with previously published
evidence and guidelines [8, 10, 18].
Methods
Study setting
Patients are recruited in the anaesthesiology departments
of the Cantonal Hospital of Baden and the University
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Hospital of Basel in the preoperative setting. We adhered
to the standard protocol items: recommendation for inter-
ventional trials (SPIRIT) figure in preparing the schedule
of enrolment, interventions and assessments (see Fig. 1)
and the SPIRIT checklist for recommendations for
standard protocol items for interventional trials (see
Additional file 1).
Eligibility criteria
Inclusion criteria
Patients undergoing either elective or emergency surgery
can be screened for eligibility. Participants fulfilling the
following inclusion criteria are eligible for the study:
– Adult patients age 65 years or older
– Scheduled for surgery within the following fields:
○ Visceral
○ Orthopaedic
○ Vascular
○ Gynaecological
○ Cardiac
○ Thoracic
– Receive general or combined anaesthesia for their
surgery
– Signed informed consent agreement
Exclusion criteria
Participants meeting the following criteria are excluded
from the study:
– Delirium upon hospital admission or during the
course of the hospital stay or Mini Mental State
Examination (MMSE) score < 24 points or a
Delirium Observation Screening Scale (DOS) score
≥ 3 points
– Dementia
– High risk of postoperative treatment in the intensive
care unit (ICU) (standard procedure excluded)
– Known haloperidol or ketamine intolerance
– Lack of cooperation or lack of communication
possibilities
○ Speech disorders
○ Isolation
○ Aphasia
○ Coma
○ Terminal illness
○ Drug or alcohol abuse
– QT interval (QTc) prolongation (≥ 460 ms in men,
≥ 470 ms in women) or drugs influencing QT
interval (see Appendix)
– Parkinson’s disease
Fig. 1 Study period overview (SPIRIT figure)
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– Parkinsonism
– Intake of dopaminergic drugs (levodopa, dopamine
agonists)
– Epilepsy
– Delay of surgery for > 72 h after set indication for
surgery
– Body weight > 100 kg
– Patient is unable to read German
Interventions
Participating patients are randomly allocated to one of
four study groups: one receiving haloperidol, one receiving
ketamine, one receiving both haloperidol and ketamine,
and one receiving placebo (Table 1). Patients are adminis-
tered the active comparator or the placebo comparator
only once right before the induction of anaesthesia. Three
follow-up days are scheduled beginning on the first
postoperative day.
The study period consists of enrolment, allocation, post-
allocation and closeout (Table 2). Allocation is defined as
the time point at which the patient is randomised to one
of the four treatment arms. Closeout is defined by either
the last day of in-hospital follow up or the follow up
assessed by a telephone call in the case of preterm hospital
discharge.
The investigators will preoperatively and postoperatively
test cognitive function with the Mini Mental Status Exam-
ination (MMSE), the Delirium Observation Scale (DOS),
the Nursing Delirium Screening Scale (Nu-DESC) or the
Intensive Care Delirium Screening Checklist (ICDSC)
(Fig. 1). In addition, preoperative and postoperative corti-
sol, neuron specific enolase (NSE) and S-100 calcium-
binding protein B (S-100B or S-100β) levels will be mea-
sured. If the study participant is discharged from the hos-
pital before the scheduled 3 follow-up days are terminated
he or she will be contacted by telephone and the conversa-
tion will be documented in a free-text field on the case re-
port form.
Outcomes
Primary outcome measure
Superiority of one of the active comparator treatment
arms in patients after surgery for prevention of
hypoactive, hyperactive or mixed delirium, which is
assessed by 2-point drop in MMSE score when assessed
during one of the 3 postoperative days.
Secondary outcome measures
Incidence of postoperative delirium based on cognitive
testing and laboratory parameters:
– A 1-point drop in Nu-DESC score on 1 of the 3
postoperative days
– Significant elevation of study-specific laboratory
values after surgery:
○ Elevation of NSE above 16.3 μg/l (normal
value)
○ Elevation of S-100β above 0.1 μg/l (normal
value) or doubling of the preoperative value
○ Elevation of cortisol level above 638 nmol/l
(upper limit of normal range)
Sample size
Sample size was estimated to be able to show the super-
iority of one treatment arm to placebo by a 30% reduc-
tion in the incidence of delirium (efficacy). To achieve
power of 0.8, 188 study participants will have to be
recruited. To accommodate for drop-out cases the
sample size has been increased to 200 (i.e., 50 study
participants to be recruited for each treatment arm).
Recruitment
All consecutive patients aged 65 years or older sched-
uled for surgery will be screened for study eligibility and
then recruited if consent is given.
Allocation
Sequence generation
The allocation sequence follows computer-generated
random numbers provided by the Clinical Trials Center
(CTC) Zurich. To reduce predictability of the random
sequence, the lists are stored in the office of the head
nurse with no access permitted by any member of the
study team.
Allocation concealment mechanism
Study envelopes containing information on the treatment
arm allocated to a specific study participant are assembled
by designees who are not member of the study team. For
each study participant, two sealed envelopes are prepared:
one regular envelope to be handed out to the nurses who
prepare the study drug and one emergency envelope to be
opened in case of an adverse event. The sealed emergency
envelope is stored with the documents detailing the
patient’s current and past medical history to guarantee
complete access in case of an emergency.
Table 1 Overview of treatment arms
Treatment arms Assigned interventions
Active comparator: haloperidol Haloperidol 0.005 mg/kg body
weight at induction of anaesthesia
Active comparator: ketamine Ketamine 1 mg/kg body weight at
induction of anaesthesia
Active comparators: haloperidol
+ ketamine in combination
Haloperidol 0.005 mg/kg body
weight + ketamine 1 mg/kg body
weight at induction of anaesthesia
Placebo comparator Normal saline (NaCl 0.9%)
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Implementation
The allocation sequence follows successive numbers from
1 to 200. Participants may be enrolled by every study team
member based on the previously described schedule. After
consent is given, the sealed envelope that contains the
corresponding allocation number is then handed over to
the nurse who prepares the study drug. Preparation study
drug(s) is controlled by a member of the study team who is
not involved in the recruitment process or the follow-up of
the specific study participant. The study drug is then
administered by the anaesthesiologist who also is not
member of the study team. All scheduled delirium assess-
ments, except for the MMSE, are performed by the nurses
responsible for the care of the study participant except.
The MMSE is conducted by a member of the study team.
Blinding
Trial participants and care providers including the anaes-
thesiologist administering the study drug are blinded. The
study drugs are prepared as follows to avoid assumption
by any colour difference from the placebo (see Table 2 for
weight dependent dosing). This adds to a total of 40 ml
solution administered slowly to every patient:
1. Trial arm haloperidol: one 20 ml syringe containing
the appropriate concentration of haloperidol, and
one syringe containing 20 ml NaCl 0.9%
2. Trial arm ketamine: one 20 ml syringe containing
the appropriate concentration ketamine, and one 20
ml syringe containing NaCl 0.9%
3. Trial arm haloperidol + ketamine: one 20 ml syringe
containing the appropriate concentration
haloperidol, and one 20 ml syringe containing the
appropriate concentration ketamine
4. Trial arm placebo: two syringes, each containing 20
ml NaCl 0.9%
Data collection
All participants in the study will be provided a participant
information sheet describing the study and providing
sufficient information to enable the participant to make
an informed decision about their participation in the
study. The patient information sheet and the consent form
will be submitted to the competent ethics committee to
be reviewed and approved. The formal consent of a par-
ticipant, using the approved consent form, must be ob-
tained before the participant is subjected to any study
procedure. The participant should read and consider the
statement before signing and dating the informed consent
form and should be given a copy of the signed document.
The consent form must also be signed and dated by the
investigator (or his designee). The signed form will be
retained as part of the study records.
The patient will be informed on the possibility to with-
draw their data from the study at any time and without
needing to provide any explanation. In the case of
discontinuation from trial participation, the data
collected (i.e., measured laboratory values) will be used
for publication if the patient does not object. In the case
of deviation from the study protocol, patient data will be
destroyed and thus not used for publication. Patients
discharged from the hospital before the 3-day follow up
post-surgery will be contacted by phone to assess their
wellbeing. The collected data will be used for publication
in these cases.
Data will be entered into a web-based electronic case
report form (eCRF) established by the CTC Zurich
(secuTrial®). Paper case report forms will be used in
parallel also because of possible technical difficulties.
Trial staff will have exclusive access 24 h per day, 7 days
per week, to the electronic case report for data entry. A
unique patient identification code will be assigned
electronically to every randomised patient.
Trial medication
Patients enrolled in the trial will be randomised to receive
either haloperidol (Haldol®, concentrated 5 mg/ml for
intravenous (iv) administration, Janssen-Cilag AG, Zug,
Switzerland), ketamine (Ketalar®, concentrated 50 mg/ml
for iv administration, Pfizer AG, Zurich, Switzerland),
Table 2 Weight-dependent dosing
Haloperidol: 5 μg/kg body weight diluted in NaCl 0.9%, haloperidol 5 mg/ml concentrate
Weight (kg) Haloperidol (mg) NaCl (ml) Weight (kg) Haloperidol (mg) NaCl (ml)
40–50 0.5 19.5 71–80 0.8 19.2
51–60 0.6 19.4 81–90 0.9 19.1
61–70 0.7 19.3 91–100 1.0 19.0
Ketamine: 1 mg/kg body weight diluted in NaCl 0.9%, ketamine 50 mg/ml concentrate
Weight (kg) Ketamine (mg) NaCl (ml) Weight (kg) Ketamine (mg) NaCl (ml)
40–50 50 19.0 71–80 80 18.4
51–60 60 18.8 81–90 90 18.2
61–70 70 18.6 91–100 100 18.0
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both drugs combined or NaCl 0.9% (NaCl 0.9% B. Braun®
for iv administration, B. Braun Medical AG, Sempach,
Switzerland) administered right before induction of
anaesthesia to prevent postoperative delirium.
Delirium assessment tools
For delirium assessment, the MMSE, DOS and Nu-
DESC will be assessed preoperatively to avoid inclusion
of patients suffering from cognitive decline prior to
surgery. These three tests will be assessed daily one first
3 postoperative days to document the course after
surgery and to detect the potential development of
postoperative delirium. The MMSE and Nu-DESC will
be assessed once daily, and the DOS will be assessed
during every nursing shift. Data collection forms are
available online in German and English.
The MMSE score is an assessment tool used in
nearly all medical fields. The MMSE is a 30-item
checklist of symptoms suggestive of cognitive decline.
Patients lose 1 point for each symptom that manifests
during the specified time frame: 1 point is taken if
the question cannot be answered, if it is answered in-
correctly or if the demanded task cannot be executed
by the patient. Overall, orientation in time and place,
retentiveness, short-term memory, language and text
comprehension, presence of agraphia, apraxia, agno-
sia, and executive functions (e.g., action planning) are
evaluated. A total of 30 points can be achieved. No
cognitive decline is suspected in patients who achieve
27 points. A total of 26 points is considered the
threshold value. A total MMSE score of fewer than
24 points is indicative of cognitive limitations. There-
fore, patients with an MMSE score below 24 points
or a DOS score of at least 3 points preoperatively are
not recruited for the study.
The DOS represents a screening tool that has been
specifically developed for the assessment of conspicuous
behavioural traits suggestive of cognitive decline by the
nursing team responsible for the care of a patient. It is
based on observations made according to a 13-item
checklist that is used during every shift, usually over a
period of 3 days. In our study, the DOS score is assessed
preoperatively and on postoperative days 1–3. One con-
dition for DOS score interpretation is the assessment of
an additional tool for the estimation of cognitive
function when the DOS score suggests cognitive decline
(i.e., DOS score ≥ 3 points) [19].
The Nu-DESC is a delirium screening tool that has
been translated into German in accordance with the
guidelines [20]. Based on the Nu-DESC assessment tool,
Gaudreau et al. have developed an easy-to-use, nursing-
based measurement tool that can be easily integrated in
everyday practice [20].
If the patient has to be treated in the ICU after
surgery, the ICDSC score is documented during every
shift. The ICDSC is among the most well-studied and
widely implemented adult ICU delirium screening
tools worldwide and has been recommended by re-
cently updated clinical practice guidelines. The ICUs
of the University Hospital of Basel routinely use the
ICDSC for assessment of delirium. Based on high-
quality evidence, it has been recommended for the
screening of delirium in ICU by the Society of Crit-
ical Care Medicine [7]. A score ≥ 4 indicates a posi-
tive ICDSC and the presence of delirium [7, 21].
Laboratory assessments of cognitive function
NSE Elevated NSE can be measured in the blood (half-life
of roughly 48 h) or the cerebrospinal fluid (half-life of 6–8
h) and is indicative of various pathological conditions. It
serves as a marker of acute neuronal lesions as in anoxia,
acute brain injury, or inflammatory processes leading to
cell destruction. NSE levels are negligible after damage to
extracerebral tissue. NSE is quantified in acute brain in-
jury, subarachnoid haemorrhage, stroke, status epilepticus,
dementia, active multiple sclerosis, severe central nervous
system (CNS) infection, decompensated hypertension, in-
tracerebral and extracerebral neoplasia, cardiopulmonary
bypass during heart surgery, cardiac arrest, and
neurological metabolic diseases for course documentation
and prognostic evaluation.
Although elevated NSE is associated with above-
mentioned conditions, Rasmussen et al. identified a
significant decrease in NSE after abdominal surgery in a
study of 65 patients, but this did not correlate with cogni-
tive dysfunction [22]. Other studies with larger cohorts
also showed no difference in NSE levels in delirious and
non-delirious patients after investigation of elderly pa-
tients who were acutely admitted after hip fracture [23].
However, other data suggest correlation between elevated
NSE and delirium in the ICU population [24]. We
conclude that the role of NSE in the diagnosis of delirium
and its possibility to evaluate long-term outcome is still
unclear and needs further investigation.
S-100β S-100 proteins play a role in the regulation of
various cellular processes (e.g., cell cycle progression
and differentiation) and can be localised in the cyto-
plasm and/or nucleus of numerous types of cells [25].
Altered levels have been connected to several diseases
including Alzheimer’s disease [26], Down’s syndrome
[27], epilepsy [28, 29], amyotrophic lateral sclerosis
[30, 31], melanoma [32–34], type I diabetes [35, 36]
as well as in several neurological [37] and neoplastic
diseases [38].
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Study results on S-100β are also inconclusive for delir-
ium. A study interpreted elevated levels of S-100β as either
a marker of cerebral damage or as a consequence of delir-
ium or cerebral damage that could lead to delirium [23].
While delirious patients in this study had the highest levels
of S-100β, calling for further investigation to elucidate
its role in the pathophysiological pathway that leads
to delirium [23], another study found no significant
difference in S-100β in delirious compared to non-
delirious patients but this was specifically in a critic-
ally ill cohort [24]. To resolve this uncertainty, we
would like to profoundly investigate this marker in
postoperative delirium.
Cortisol Serum cortisol levels have been shown to cor-
relate with both the degree of delirium and the risk of
developing it, as stress was found to play a major role in
delirium and its pathogenesis postoperatively [39].
Serum cortisol has been suggested to be an important
marker of risk of postoperative delirium after cardiac
surgery in patients with a preoperative diagnosis of
major depressive disorder [40].
Serum cortisol levels depend on the patients’ peri-
operative stress levels. To date, there remains no clear
definition of physiological vs. pathological serum cortisol
levels following a certain type of surgery. The present
study will analyse cognitive decline or present delirium
based on the mentioned scores and correlation between
serum cortisol levels preoperatively vs. postoperatively.
Electrocardiogram
To evaluate the possible consequences of a potential
side effect of haloperidol (i.e., prolongation of the QT
interval), we will record an ECG preoperatively and
48 h after surgery. One study demonstrated QT
prolongation after intravenous administration of halo-
peridol to be moderately correlated with the dose ad-
ministered and recommends clinicians to be aware of
this correlation [41]. It is recommended that haloperi-
dol should be discontinued if QTc exceeds 500 ms
due to elevated risk of arrhythmia (e.g., torsade de
pointes) [42]. Since the elimination half-life is esti-
mated to be 20 h, we will repeat the ECG 48 h after
surgery to protect patient safety.
Data management
All data from this study will be kept within the Trial Mas-
ter File, and only the study team will have access. In case
of a patient’s retroactive denial of study participation, the
data collected will not be used for publication in the
present or in future trials. In such cases, the data will be
destroyed.
All study data will be archived in a designated place
on the Surgical Intensive Care Unit at the University
Hospital of Basel for a minimum of 10 years after study
termination or premature termination of the clinical
trial. We plan to store the data also within an eCRF.
Statistical methods
Null and alternative hypothesis
The two-sided statistical null hypothesis will test
whether the preoperative administration of haloperidol,
ketamine or both drugs combined immediately before
induction of anaesthesia compared to placebo is unable
to prevent the decline of postoperative cognitive func-
tion. The alternative hypothesis is that there is an effect
of one of the drugs or the combination.
Planned analyses and sample size rationale
Primary analysis Differences among the four groups
will be analysed by the chi-square test. Post hoc the
groups will be compared by pairwise chi-square test
including the Bonferroni correction.
We will follow the intention-to-treat principle. Data
on all study participants who have received the study
drug as part of one of the four treatment arms will be
analysed.
When the sample size in each of the four groups is 50,
the 0.05-level chi-square test will have 80% power to de-
tect a difference in proportions characterised by variance
(V) of proportions:
V = Σ(πi- π0)
2/G of 0.0125 and an average proportion
of 0.35
Since study participants will be excluded from the
primary analysis if there is a significant decline in
MMSE score of at least 2 points during at least 1 of
the 3 postoperative days or if they are treated in the
ICU after surgery. The determined sample size follow-
ing power analysis will be increased (see above). This
might lead to an uneven number of study participants
distributed over the four treatment arms after termin-
ation of the study, an occurrence that will need to be
taken into consideration.
Secondary analyses These consist of the quantification
of the incidence of postoperative delirium and measured
changes in the assessed laboratory parameters including
NSE, S-100β and cortisol, and the lowest Nu-DESC
scoring (of at least 1 point) after surgery. The delirium
assessment tools will be evaluated for their reliability. It
will be compared if the results of the various assessment
tools correlate with diagnosis of delirium.
Interim analyses No interim analyses are planned for
this study.
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Deviation(s) from the original statistical analysis plan
Statistical analyses will begin after all study participants
have been recruited for the study. If for whatever reason
substantial deviations of the analysis, as outlined in this
section, are needed, the responsible Ethics Committees
will be informed immediately. All deviations from the
analysis detailed in the protocol will be listed and ratio-
nalised in the final statistical report.
Handling of missing data and drop-outs
Data from study participants who have received the
study drug as part of one of the four treatment arms
and who were assessed for delirium as declared and
who have not been treated in the ICU following sur-
gery can be integrated in the analysis of the primary
endpoint. All missing data will be documented in the
CRF and described in detail within the publication.
Missing values on the secondary endpoint will not be
assigned (complete case analyses).
Data monitoring
No regular monitoring visits at the investigator’s site are
planned by the sponsor. The eCRF will be monitored daily
by a member of the study team. The source data/docu-
ments will be accessible to monitors, and questions will be
answered during possible monitoring. The CTC Zurich will
enable monitoring at the study centres. The monitoring
follows designated standard operating procedures (SOP).
Adverse events
Individual participants will be excluded from the study
in the case of an adverse event that in the opinion of the
sponsor contraindicates study drug administration
(emergency setting).
Serious adverse event (SAE)
An SAE is classified as any medical occurrence that re-
sults in death, is life-threatening, requires prolongation
of existing hospitalisation, or results in persistent or
significant disability/incapacity. The occurrence of SAEs
will be assessed based on the bedside visit and study of
vital and laboratory parameters and will be recorded
daily on the eCRF.
All changes in research activity and unanticipated
problems will be reported to the competent Ethics Com-
mittee by the sponsor and the principal investigator. An
SAE or a serious unexpected adverse drug reaction
(SUSAR) must be reported within 7 days maximum if
fatal, otherwise within 15 days. An annual safety report
will be provided by the sponsor.
Serious unexpected adverse drug reaction (SUSAR)
A SUSAR indicates an adverse drug reaction that is of a
nature or severity that is not consistent with the applic-
able product information.
Auditing
To verify trial conduct with respect to good clinical
practice (GCP) guidelines, audits and inspections can be
executed by the competent authorities involved (i.e.,
Swissmedic, indicated ethics committees) at any time.
Access to all study-specific documents and the corre-
sponding source data is guaranteed at all times. The
sponsor and the principal investigator guarantee and
answer for all upcoming questions. All involved
persons will treat study participant data with full
confidentiality.
Ethics and dissemination
Research ethics approval
Approval to conduct this study was granted by the
Ethics Committee of the canton of Aargau (KEK:
2012–037), the Ethics Committee of Northwestern and
Central Switzerland (EKNZ: AGSO 2012/037) and the
Competent Authority (Swissmedic: 2013DR4089). The
study is registered at the Swiss National Clinical Trial
Portal (SNCPT; Identifier: SNCTP000001628) and at
ClinicalTrials.gov (Identifier: NCT02433041).
This study is conducted in compliance with the proto-
col, the current version of the Declaration of Helsinki,
the ICH-GCP or ISO EN 14155 (as far as applicable) as
well as all national legal and regulatory requirements.
Protocol amendments
No amendments have been declared prior to submission
of the protocol for publication.
Consent or assent
The investigators will explain to each participant the na-
ture of the study, its purpose, the procedures involved,
the expected duration, the potential risks and benefits
and any discomfort it may entail. Each participant will
be informed that the participation in the study is volun-
tary, that he/she may withdraw from the study at any
time and that withdrawal of consent will not affect his/
her subsequent medical assistance and treatment. The
participant must be informed that his/her medical
record may be examined by authorised individuals other
than their treating physician. Only members of the study
team will be eligible to seek patient consent or assent for
study participation.
Confidentiality
Collection, documentation, saving and interpretation of
personal data in conjunction with this clinical trial
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conforms to updated Swiss data protection regulations.
Voluntary participation of the study participant granted
by his or her signature in the study-specific consent
form is a prior condition of this study.
Data collected from the study participants during this
trial are treated as highly confidential and cannot be
transferred to third parties. Confidentiality is guaranteed
by assignment of a participant ID number without the
possibility of inferring the participant’s identity. With
prior consent of the study participant, his or her
information can be forwarded to the family doctor or
other treating physicians to assure the patient’s well-
being. The collected study-specific data can be inspected
and reviewed for verification purposes by monitors of
the involved ethics committees or other competent
authorities.
Declaration of interests
Each of the authors declares that there are no conflicts
of interest.
Access to data
See Data management.
Ancillary and post-trial care
Apart from the 3 days scheduled for follow up after
surgery, no additional follow up is planned for this
study. In the case of any questions or concerns after
hospital discharge, contact data are indicated within the
patient information form handed out to gain the
patient’s consent for study participation.
To compensate those who suffer harm from trial
participation, insurance will be provided by the sponsor
based on the liability insurance of the Cantonal Hospital
of Baden and the University Hospital of Basel.
Dissemination policy
Study results will be communicated to patients based on
expected speed-up in recruiting all 200 foreseen study
participants. During the ongoing study and until publi-
cation, there will be no public access to the data. We
plan to publish the data in a major peer-reviewed clinical
journal. A public description of the study in German will
be available on the Swiss National Clinical Trial Portal
(SNCTP) after gaining approval for conduct of the study
from the competent ethics committee.
Discussion
Trial rationale
Delirium is a serious condition calling for prompt
diagnosis and treatment. We hypothesise that the ad-
ministration of haloperidol, ketamine or both com-
bined immediately before induction of anaesthesia
compared to placebo will lead to a reduced incidence
of postoperative delirium. Clinical care for patients
might improve as the results of this study may lead
to better algorithms for the prevention of delirium.
By achieving the goal, this trial could reduce the bur-
den on family members and might protect the
patient’s long-term autonomy and health and eventu-
ally diminish delirium-associated mortality.
Population
This study will include patients admitted to the hospital
prior to scheduled or emergency surgery without
preoperative impaired cognitive function.
Intervention
There is limited but promising evidence that haloperidol
and ketamine can be used to prevent delirium. In our
trial, we aim to confirm the superiority of one or more
of the non-placebo treatment arms over placebo for the
prevention of delirium.
Outcome
Based on evidence that haloperidol and ketamine both
prevent delirium, we chose to evaluate the effect of these
drugs, administered alone or in combination, on the
incidence of postoperative delirium to be able to
calculate a significant reduction and thereby prove our
hypothesis.
Sample size
As described above, sample size was estimated to be able
to show the superiority of one of the three non-placebo
treatment arms compared to placebo on reducing the
incidence of postoperative delirium.
Perspective
The Baden PRIDe Trial aims to reduce the incidence of
postoperative delirium by investigating the three non-
placebo treatment arms for the development of a
prevention regime for postoperative delirium based on
high-quality data.
Trial status
The ethics committee of the canton of Aargau granted
approval of this study in May 2013. Inclusion of first pa-
tient was in July 2013. Between July 2013 and August
2017, a total of 171 patients were recruited. The final
results are expected in the first half of 2018. Due to
ongoing data collection, currently no data are publicly
available. Results will be submitted to peer-reviewed
journals for publication and will be presented at relevant
academic conferences.
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Appendix
Additional file
Additional file 1: SPIRIT checklist. (DOC 115 kb)
Abbreviations
CNS: Central nervous system; CTC: Clinical Trials Center (Zurich);
DOS: Delirium Observation Scale; ECG: Electrocardiogram; eCRF: Electronic
case report form; ICDSC: Intensive Care Delirium Screening Checklist; ICH-
GCP: International Council for Harmonisation of Technical Requirements for
Pharmaceuticals for Human Use - good clinical practice; ICU: Intensive care
unit; MMSE: Mini Mental Status Examination; NSE: Neuron specific enolase;
Nu-DESC: Nursing Delirium Screening Scale; PRIDe: Prevention and Reduction
of Incidence of postoperative Delirium Trial; S-100β: S-100 calcium-binding
protein B; SAE: Serious adverse event; SNCTP: Swiss National Clinical Trial
Table 3 Overview of drugs causing QT prolongation (Schweiz
Med Forum 2007;7:814–819)
Drug group Drug
Antiarrhythmic agents Amiodarone (Cordarone ®)
Disopyramide (Norpace ®)
Quinidine (Kinidin-Duriles ®)
Sotalol (Sotalex ®)
Flecainide (Tambocor ®)
Ibutilide (Corvert ®)
Other cardiovascular drugs Dobutamine, dopamine
Ephedrine
Epinephrine
Indapamide (Fludex SR ®)
Isradipine (Lomir SRO ®)
Midodrine (Gutron ®)
Norepinephrine
Psychotropic drugs Amitriptyline (Saroten ®)
Chloral hydrate (Chloraldurat ®,
Medianox ®, Nervifene)
Citalopram
Chlorpromazine (Chlorazin ®)
Clomipramine (Anafranil ®)
Doxepine (Sinquan ®)
Felbamate (Taloxa ®)
Fluoxetine (Fluanxol ®, Deanxit ®)
Galantamine (Reminyl ®)
Haloperidole (Haldol ®)
Imipramine (Tofranil ®)
Levomepromazine (Nozinan ®)
Lithium (Priadel ®, Neurolithium ®)
Methadone (Ketalgin ®)
Methylphenidate (Concerta ®, Ritalin ®)
Nortriptyline (Nortrilen ®)
Olanzapine (Zyprexa ®)
Paroxetine (Deroxat ®, Parexat ®)
Quetiapine (Seroquel ®)
Risperidone (Risperdal ®)
Sertindole (Serdolect ®)
Sertraline (Zoloft ®, Gladem ®)
Thioridazine (Melleril ®, Melleretten ®)
Tizadinine (Sirdalud ®/-MR)
Trimipramine (Surmontil ®, Trimin ®)
Venlafaxine (Efexor ®)
Gastrointestinal Dolasetrone (Anzemet ®)
Domperidone (Motilium ®/-lingual)
Table 3 Overview of drugs causing QT prolongation (Schweiz
Med Forum 2007;7:814–819) (Continued)
Drug group Drug
Granisetrone (Kytril ®)
Octreotide (Sandostatine ®)
Ondansetrone (Zofran ®)
Phentermine (Adipex ®)
Sibutramine (Reductil ® 10/15, Ionamin ®)
Respiratory Salbutamole (Ventolin ®)
Salmeterole (Serevent ®, Seretide ®)
Terbutaline (Bricanyl ®)
Antibiotics Azithromycine (Zithromax ®)
Ciprofloxacine (Ciproxin ®)
Clarithromycine (Klacid ®)
Erythromycine (Erythrocin ®)
Levofloxacine (Tavanic ®)
Moxifloxacine (Avalox ®)
Ofloxacine (Tarivid ®)
Roxithromycine (Rulid ®)
Trimethroprim-Sulfamethoxazole
(Bactrim ®, Cotrim ®)
Antiviral agents Amantadine (Nivaquine ®, Chlorochin ®)
Mefloquine (Lariam ®, Mephaquin ®)
Antifungal agents Pentamidine (Pentacarinat ®)
Fluconazole (Diflucan ®)
Itraconazole (Sporanox ®)
Ketoconazole (Nizoral ®)
Voriconazole (Vfend ®)
Miscellaneous Alfuzosine (Xatral ®)
Phenylephrine
Phenylpropanolamine (Kontexin ®,
Rhinotussal ®)
Pseudoephedrine (Otrinol ®, Benical ®)
Tacrolimus (Prograf ®, Protopic ®)
Tamoxifen (Tamoxifen ®, Nolvadex ®)
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Portal; SOP: Standard operating procedure; SUSAR: Serious unexpected
adverse drug reaction
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